arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Entrada Therapeutics, Inc.

TRDA
$6.86 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Entrada Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $287.0M
Dividend Yield
Revenue Growth -95.7%
Op. Margin None
ROIC -12.3%
FCF / Share $-1.00
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$875.00K
↓ -95.7%
Net Income Profit after all expenses
$-39.72M
↓ -128.9%
Operating Margin Operating profit as % of sales
-106.0%
↓ -575.6%
FCF / Share Free cash flow per share
$-1.00
↓ -3.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters